Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Generics Research Forges Ahead After Agency’s Bupropion Mea Culpa

Dec 10 2012

• By Nielsen Hobbs

Related Content

FDA’s Latest PR Push: Protecting the Reputation of Generic Drugs

Apr 09 2012

Generic Bupropion XL Must Be Retested; Teva/Impax 300 mg Withdrawn After Efficacy Concerns

Oct 04 2012

Related Companies

Amneal Pharmaceuticals, Inc.

Teva Pharmaceutical Industries Ltd.

GSK plc

Astellas Pharma, Inc.

Additional Topics

United States Post Market Regulation & Studies Drug Approval Standards BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window